Mesoblast has secured exclusive global rights to a CAR technology platform to engineer its MSC therapies for more precise targeting and greater potency in inflammatory and autoimmune diseases, including bowel disease and lupus nephritis.
The new grants will support diverse early-stage research projects, aiming to advance regenerative medicine tools and future therapies.
The Australian biotech company is preparing for trials and commercialization of its stem cell therapy platform for Crohn's disease, StemSmart.
NeuroScientific brings Dr. Cole onboard as it advances stem cell research and prepares for clinical trials.
The FDA has recently approved them for what appears to be an expanded adipose MSC trial, looking for GI experienced physicians.
What appears to be a small stem cell banking company is working on expanded adipose stem cell therapy for various autoimmune conditions.